Intensity Therapeutics Inc. (INTS)
(Delayed Data from NSDQ)
$0.28 USD
+0.01 (3.70%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $0.28 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
INTS 0.28 +0.01(3.70%)
Will INTS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for INTS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INTS
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
INTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INTS
Crossed Above 50 Day Moving Average appears for INTS after 3.7% move
Is INTS preparing to trend higher? Crossed Above 50 Day Moving Average shows up after rocketing 8.15%
Is INTS primed for upward momentum? Crossed Above 20 Day Moving Average shows up after rallying 6.22%
Technical picture remains unchanged for INTS after it falls 1.1% on September 30
12 Health Care Stocks Moving In Wednesday's Pre-Market Session